Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fate Therapeutics (FATE) Research & Development (2016 - 2025)

Historic Research & Development for Fate Therapeutics (FATE) over the last 14 years, with Q3 2025 value amounting to $25.8 million.

  • Fate Therapeutics' Research & Development fell 2543.15% to $25.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $116.0 million, marking a year-over-year decrease of 1290.84%. This contributed to the annual value of $135.0 million for FY2024, which is 2178.21% down from last year.
  • Fate Therapeutics' Research & Development amounted to $25.8 million in Q3 2025, which was down 2543.15% from $27.4 million recorded in Q2 2025.
  • Fate Therapeutics' 5-year Research & Development high stood at $87.2 million for Q4 2022, and its period low was $25.8 million during Q3 2025.
  • Its 5-year average for Research & Development is $48.7 million, with a median of $40.9 million in 2023.
  • In the last 5 years, Fate Therapeutics' Research & Development soared by 8007.05% in 2021 and then plummeted by 6351.0% in 2023.
  • Quarter analysis of 5 years shows Fate Therapeutics' Research & Development stood at $69.5 million in 2021, then rose by 25.43% to $87.2 million in 2022, then tumbled by 63.51% to $31.8 million in 2023, then increased by 5.64% to $33.6 million in 2024, then decreased by 23.12% to $25.8 million in 2025.
  • Its Research & Development stands at $25.8 million for Q3 2025, versus $27.4 million for Q2 2025 and $29.1 million for Q1 2025.